To further establish clinical relevance of the Sema3A/NRP1 axis in GBM, we determined the expression levels of each of the signaling components in GBM specimens by tissue microarray (TMA), in which 68 GBM specimens and 10 non–tumor-bearing brain tissues were included (Figure 8A). This evidence concerns the gene SEMA3A and neoplasm.